Optical Monitor Continuously Measures Glucose Levels

A new diabetes monitor uses optical spectroscopy to detect blood glucose levels by shining light through the skin and detecting changes in the returning spectrum.

The C8 Medisensors Optical Glucose Monitor System is a novel noninvasive continuous glucose monitor (nCGM) that harnesses the power of light to measure glucose levels. The small, pain-free portable monitor uses Raman spectroscopy, shining a beam of monochromatic light into the skin, with the resulting vibrations of scattered light from glucose molecules measured to give a glucose reading. The colors generated by Raman scattering are very specific to the exact chemical structure of the molecules, with various shapes, sizes, atoms, and types of chemical bonds generating a unique Raman spectra that can be used to noninvasively read and measure glucose.


The device does not require constant recalibration to maintain sensor accuracy. And apart from periodic baseline reference measurements, there is no need for ongoing finger sticks to constantly recalibrate the device; after being removed and put back on, the monitor will resume measuring glucose. For added convenience, the readings can be stored and subsequently sent wirelessly via Bluetooth to the user's smartphone, providing a continuous picture of glucose dynamics throughout the day. The C8 Medisensors optical glucose monitor system is a product of C8 MediSensors (San Jose, CA, USA), and has received the European Community CE marking of approval.

“C8 MediSensors was cofounded by a father trying to help his son living with diabetes, and as a company, we remain dedicated to helping those with the disease,” said Paul Zygielbaum, CEO of C8 MediSensors. “Our team is hugely excited to be working to make nCGM and the Optical Glucose Monitor System available throughout Europe.”

In clinical studies, the C8 MediSensors monitor was found to have accuracy comparable to earlier versions of invasive continuous glucose monitors (CGMs) when those systems were first introduced, but with less pain and less risk of infection. It is contraindicated in pregnancy and for those under 18 years of age, as well as in individuals with very light or very dark skin tones, peripheral vascular disease, or individuals who smoke.

Related Links:
C8 MediSensors